Witte K K A, Cleland J G F, Clark A L
University of Hull, Hull, UK.
Heart. 2006 Apr;92(4):481-6. doi: 10.1136/hrt.2004.058073. Epub 2005 Sep 13.
To establish the prevalence of chronotropic incompetence in a cohort of patients with chronic heart failure (CHF) taking modern medications for heart failure, and whether this affected exercise capacity and predicted prognosis.
Heart rate response to exercise was examined in 237 patients with CHF in sinus rhythm, who were compared with 118 control volunteers. The percentage of maximum age predicted peak heart rate (%Max-PPHR) and percentage heart rate reserve (%HRR) were calculated, with a cut off of < 80% as the definition of chronotropic incompetence for both. Patients were followed up for an average (SD) of 2.8 (9) years. Mortality was related to peak oxygen consumption (pVo2), and the presence or absence of chronotropic incompetence.
%Max-PPHR < 80% identified 103 (43%) and %HRR < 80% identified 170 patients (72%) as having chronotropic incompetence. Chronotropic incompetence was more common in patients taking beta blockers than in those not taking beta blockers as assessed by both methods (80 (49%) v 23 (32%) by %Max-PPHR and 123 (75%) v 47 (64%) by %HRR, respectively). Patients with chronotropic incompetence by either method had a lower pVo2 than those without. These differences remained significant for both patients taking and not taking a beta blocker. %HRR, Max-PPHR%, and HRR were related to New York Heart Association class and correlated with pVo2. There was no difference in the slopes relating heart rate to pVo2 between patients with and those without chronotropic incompetence (6.1 (1.7) v 5.1 (1.8), p = 0.34). During an average 2.8 year follow up 40 patients (17%) died. In Cox proportional hazard models, pVo2 was the most powerful predictor of survival and neither measure of chronotropic incompetence independently predicted outcome.
pVo2 is a powerful marker of prognosis for patients with CHF whether they are taking beta blockers or not. A low heart rate response to exercise in patients with CHF correlates with worse exercise tolerance but is unlikely to contribute to exercise impairment.
确定一组接受现代心力衰竭药物治疗的慢性心力衰竭(CHF)患者中变时性功能不全的患病率,以及其是否会影响运动能力和预测预后。
对237例窦性心律的CHF患者进行运动时心率反应检查,并与118名对照志愿者进行比较。计算最大年龄预测峰值心率百分比(%Max-PPHR)和心率储备百分比(%HRR),两者均以<80%作为变时性功能不全的定义。患者平均随访2.8(9)年。死亡率与峰值耗氧量(pVo2)以及变时性功能不全的有无相关。
%Max-PPHR<80%确定103例(43%)患者有变时性功能不全,%HRR<80%确定170例(72%)患者有变时性功能不全。通过两种方法评估,服用β受体阻滞剂的患者变时性功能不全比未服用β受体阻滞剂的患者更常见(分别为%Max-PPHR法80例(49%)对23例(32%),%HRR法123例(75%)对47例(64%))。两种方法中任何一种有变时性功能不全的患者其pVo2均低于无变时性功能不全的患者。对于服用和未服用β受体阻滞剂的患者,这些差异均具有统计学意义。%HRR、Max-PPHR%和HRR与纽约心脏协会心功能分级相关,并与pVo2相关。有变时性功能不全和无变时性功能不全的患者心率与pVo2的斜率无差异(6.1(1.7)对5.1(1.8),p = 0.34)。在平均2.8年的随访期间,40例患者(17%)死亡。在Cox比例风险模型中,pVo2是生存的最强预测因素,变时性功能不全的两种测量方法均不能独立预测预后。
无论是否服用β受体阻滞剂,pVo2都是CHF患者预后的有力标志物。CHF患者运动时心率反应低与运动耐量差相关,但不太可能导致运动功能受损。